Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study-Reference-Cited by-同舟云学术

Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study

Published:2022-07-27 Issue:10 Volume:31 Page:1039-1045
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiology and Drug

Author:

Kemp‐Casey Anna¹^ORCID,Mintzes Barbara²^ORCID,Morrow Richard L.³,Dormuth Colin R.³,Souverein Patrick C.⁴,Roughead Elizabeth E.¹

Affiliation:

1. School of Pharmacy and Medical Sciences University of South Australia Adelaide Australia

2. Charles Perkins Centre and School of Pharmacy The University of Sydney Sydney Australia

3. Department of Anesthesiology, Pharmacology & Therapeutics University of British Columbia Victoria Canada

4. Division of Pharmacoepidemiology and Clinical Pharmacology Universiteit Utrecht Utrecht The Netherlands

Funder

Canadian Institutes of Health Research

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5508

Reference27 articles.

1. Federal Drug Administration.2010.Ongoing safety review of Actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. Accessed July 21 2020.https://www.fda.gov/Drugs/DrugSafety/ucm226214.htm.

2. Health Canada.2011.Health Canada reviewing diabetes drug pioglitazone (actos) and potential risk of bladder cancer. Accessed July 21 2020.http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/13617a-eng.php.

3. European Medicines Agency.Vigtig information vedrørende pioglitazon og en lille forøget risiko for blærecancer.https://www.ema.europa.eu/en/documents/product‐information/sepioglin‐epar‐product‐information_da.pdf

4. Therapeutic Goods Administration.2011.Pioglitazone and risk of bladder cancer. Accessed April 28 2021.https://www.tga.gov.au/alert/pioglitazone-and-risk-bladder-cancer

5. Medicines and Healthcare products Regulating Agency.2011.New advice on risk of bladder cancer with the anti‐diabetic drug pioglitazone Accessed April 28 2021.http://webarchive.nationalarchives.gov.uk/20141205150130/http://MHRA.gov.uk/safetyinformation/safetywarningsalertsandrecalls/safetywarningsandmessagesformedicines/con123285